AlrestatinAlternative Names: Alrestatin sodium; AY 22844
Latest Information Update: 24 Nov 1994
At a glance
- Originator Wyeth
- Mechanism of Action Aldehyde reductase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Diabetic complications
Most Recent Events
- 24 Nov 1994 Discontinued-II for Diabetic complications in USA (Unknown route)